TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22823594
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally twice daily for 2.5 days
Study: 10596204
Drug: Cisatracurium priming
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium priming (0.01 mg/kg)
Study: 10596204
Drug: Pancuronium priming
Normalized name: pancuronium
DrugBank: Pancuronium (DB01337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pancuronium priming (0.015 mg/kg)
Study: 1882007
Drug: Buspirone, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone, 15 mg per day
Study: 28981503
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation of leaf of Juniperus excelsa extract
Study: 27017763
Drug: Group F
Normalized name: Prostaglandin group F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group F (low-dose and addition of fentanyl): received intrathecally 0.5% hyperbaric bupivacaine (70% of group B) with fentanyl 20 mg and epidural catheter at T12‐L1.
Study: 27017763
Drug: Group E
Normalized name: Prostaglandin group E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E (low-dose and epidural volume extension): received intrathecally 0.5% hyperbaric bupivacaine (70% of group B) and epidural catheter at L3‐4, with 10 ml saline injected 3 minutes after intrathecal injection.
Study: 27017763
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (conventional dose): received intrathecally 0.5% hyperbaric bupivacaine (10 mg; < 160 cm in height 11 mg; > 160 cm in height) and epidural catheter at T12‐L1.
Study: 24463478
Drug: Dexmedetomidine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine bolus (0.5μg/kg) after delivery and sufentanil with dexmedetomidine PCA (background infusion of 0.045μg/kg/h with a bolus of 0.07μg/kg)
Study: 21870106
Drug: Berberine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (300 mg, t.i.d., p.o.)
Study: 19608826
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution without alanyl-glutamine
Study: 18215726
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/d for 6 weeks, then increased to 10 mg/d for 20 weeks)
Study: 30888593
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (2 g/day) with a normal diet (2000 kcal/day) during 4 weeks
Study: 23953895
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) - 4000 pulses at 0.25 mJ/mm² weekly for 4 weeks
Study: 19369294
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg given twice on day 1 followed by 4 days of EE 20 microg
Study: 19369294
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg given twice on day 1 plus doxycycline 100 mg twice daily for 5 days
Study: 29462266
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily for 5 days
Study: 19369294
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily with EE 20 microg daily
Study: 16284061
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 5 days
Study: 12548256
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel gloves used 8 hours/day for 30 days
Study: 12548256
Drug: No use
Approvals — FDA: no, EMA: no, PMDA: no
Description: No use of aloe vera gel gloves (control)
Study: 8695134
Drug: Desflurane anesthesia
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane anesthesia with mivacurium infusion
Study: 8695134
Drug: Isoflurane anesthesia
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane anesthesia with mivacurium infusion
Study: 28318850
Drug: Hyperosmolar irrigation
Normalized name: HYPEROSMOTIC LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar irrigation solution (593 mOsm/L)
Study: 22389080
Drug: Social drinkers
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social drinkers exposed to drug cue imagery
Study: 12453549
Drug: Trial of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial of diuretics for diagnosis.
Study: 12453549
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of the impact of angiotensin‐converting enzyme inhibitors.
Study: 9165135
Drug: 66 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 66 Gy in 33 2 Gy daily fractions in 45-48 days (o.d.)
Study: 3119481
Drug: Standard solution
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard solution containing crystalline amino acids (3.8 g/l), xylitol (25 g/l) and sorbitol (25 g/l), accounting for a total of 900 cal/day
Study: 29316945
Drug: Academic detailing
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Academic detailing visit on appropriate prescribing of pain relief medication
Study: 24746411
Drug: Pulverized brand-name
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulverized brand-name and generic drugs containing candesartan (Atacand(®), Cansartan‐Mepha(®), Pemzek(®))
Study: 14706729
Drug: Alternative monotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative monotherapy
Study: 10803803
Drug: L-acetylcarnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine
Study: 8641911
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy consisting of prophylactic hepatic irradiation and pancreatic bed irradiation with concurrent infusional 5‐fluorouracil (200 mg/m2/day) and leucovorin (5 mg/m2/day) for 5 out of every 7 days during the 38‐day treatment sequence.
Study: 17115349
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart (BIAsp)
Study: 31566438
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACEi)
Study: 8666715
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg diazepam
Study: 8071269
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg zolpidem
Study: 9443518
Drug: 0.65+0.35 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65+0.35 g/kg ethanol
Study: 26967896
Drug: Rocuronium (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.4 mg/kg)
Study: 25012985
Drug: Telotristat etiprate
Normalized name: Telotristat etiprate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telotristat etiprate 500 mg tid
Study: 7273791
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent sequential treatment
Study: 24260764
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of erdosteine and nasal corticosteroid spray
Study: 21288804
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of IXIARO (IC51) administered 15 months after primary immunization.
Study: 19595518
Drug: Topiramate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (up to 300 mg/day)
Study: 16458598
Drug: 16-h nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-h nicotine patch
Study: 12549956
Drug: Desloratadine (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (once-daily treatment)
Study: 10965735
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral dexketoprofen
Study: 8527271
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral ketoprofen
Study: 22237311
Drug: SB-649868 30
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-649868 30 mg
Study: 8543491
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg intravenously every 8 h
Study: 8543491
Drug: Ceftazidime 250-1000
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 250-1000 mg intravenously every 8 h
Study: 8543491
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g every 8 h + amikacin 15 mg/kg/day
Study: 8543491
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g every 8 h
Study: 2394323
Drug: Low infusion
Normalized name: Solution, Multi Ingredient Topical application Solution [AVEENO POSITIVELY RADIANT MAXGLOW INFUSION DROPS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low infusion rates
Study: 7436164
Drug: Activated oral
Normalized name: typhoid vaccine, inactivated oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated oral charcoal, 6 g daily for 8 weeks
Study: 24924991
Drug: Augmented post-remission
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented post-remission therapy (regimen C) including additional eight doses of pegylated asparaginase, 18 doses of vincristine, and escalated-dose intravenous methotrexate without folinic acid rescue.
Study: 24924991
Drug: Augmented post-remission
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented post-remission therapy (regimen C).
Study: 24924991
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (treatment regimens A and B).
Study: 19916990
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg once daily for 3 months)
Study: 17515510
Drug: Topical 0.4%
Normalized name: fluoride topical 0.4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.4% retinol lotion
Study: 15477633
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg once daily)
Study: 12756078
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg once daily)
Study: 11472700
Drug: RPR 109891
Normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR 109891 (oral glycoprotein IIb/IIIa antagonist) plus aspirin
Study: 11472700
Drug: RPR 109891
Normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR 109891 (oral glycoprotein IIb/IIIa antagonist)
Study: 9551029
Drug: fluvastatin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluvastatin 60 mg/day
Study: 9551029
Drug: fenofibrate (micronized)
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fenofibrate (micronized) 200 mg/day
Study: 9551029
Drug: simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 20 mg/day
Study: 673095
Drug: Aluminum carbonate
Normalized name: ALUMINUM CARBONATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum carbonate powder in capsule form
Study: 31383235
Drug: Montelukast and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast and fluticasone (anti-inflammatory treatment) for 12 weeks
Study: 28498504
Drug: Varenicline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (2 mg/day, after 1-week dose run-up)
Study: 28498504
Drug: NRT (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT (21 mg/day decreasing to 7 mg/day)
Study: 20652250
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard care with low molecular weight heparin)
Study: 16453953
Drug: 3 component
Normalized name: Syn023 component ctb012
DrugBank: Mazorelvimab (DB17767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 component acellular pertussis vaccine (GlaxoSmithKline)
Study: 16453953
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (Havrix) as a placebo
Study: 9917047
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no steroid exposure)
Study: 2197376
Drug: Propranolol-LA, 80-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol-LA, 80-mg tablets
Study: 2197376
Drug: Atenolol, 50-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 50-mg tablets
Study: 2197376
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no beta blocker therapy)
Study: 12166539
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (MF and BDP)
Study: 12166539
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments (MF and BDP)
Study: 7002568
Drug: Verapamil 80-160
Normalized name: verapamil hydrochloride 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80-160 mg t.i.d. for 10 days
Study: 30123523
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion
Study: 14660159
Drug: Antiretroviral medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral medication adherence on drug use days
Study: 14660159
Drug: Antiretroviral medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral medication adherence on matched abstinence days
Study: 10719624
Drug: Spleen peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spleen peptide preparation (Polyerga) during chemotherapy (cisplatin/carboplatin, 5‐fluorouracil)
Study: 29402522
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/rosuvastatin 10 mg
Study: 16682725
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (GCSF) added to prophylactic antibiotics
Study: 8031229
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg/d
Study: 12715267
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg/d
Study: 2574627
Drug: Terfenadine 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 240 mg
Study: 24955752
Drug: Lurasidone (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40-160 mg/d)
Study: 10071998
Drug: Fentanyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (10 microg) added to 1.5% lidocaine (45 mg hyperbaric)
Study: 10071998
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine (45 mg hyperbaric) alone
Study: 7706761
Drug: Single UV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single UV exposure with double the patient's minimal erythema dose
Study: 7441622
Drug: Weekly reminders
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly reminders sent to two thirds of the doctors; remaining third did not receive reminders.
Study: 27555197
Drug: Caudal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal dexmedetomidine (1 μg/kg) with caudal bupivacaine
Study: 27555197
Drug: IV dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dexmedetomidine (1 μg/kg)
Study: 25001159
Drug: Ranibizumab intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab intravitreal administration
Study: 22585883
Drug: Home blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home blood pressure monitoring, weekly health coaching, and home titration of blood pressure medications (n = 129)
Study: 22585883
Drug: Home blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home blood pressure monitoring and health coaching but no home titration (n = 108)
Study: 7004446
Drug: multivalent pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multivalent pneumococcal polysaccharide vaccine
Study: 21720264
Drug: Losartan-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan-based treatment
Study: 17924869
Drug: Fenofibrate 80
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 80 mg
Study: 20662912
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate solution rinse for 60 seconds after exposure to hydrochloric acid (0.01 M, pH 2)
Study: 20662912
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate solution rinse
Study: 12467132
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of calcium + placebo
Study: 22377512
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (3-12 mg/day)
Study: 10397416
Drug: Neuroleptic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic drug therapy
Study: 30281941
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 1 week
Study: 30281941
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 2 weeks
Study: 30281941
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 1 week
Study: 30281941
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 2 weeks
Study: 28710850
Drug: BAI 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAI 160 μg/day
Study: 28710850
Drug: MDI 80
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI 80 μg/day
Study: 28710850
Drug: MDI 160
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI 160 μg/day
Study: 26034880
Drug: Dapivirine Vaginal
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine Vaginal Ring (25 mg)
Study: 26034880
Drug: Maraviroc Vaginal
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc Vaginal Ring (100 mg)
Study: 24204865
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with educational handout
Study: 24204865
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment without educational handout
Study: 30085075
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control group
Study: 21806767
Drug: Aliskiren/Amlodipine 150/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/Amlodipine 150/5 mg, then titrated to 300/10 mg
Study: 24009042
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg)
Study: 8558934
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (no G-CSF)
Study: 6343309
Drug: Split course
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split course therapy (3000 rad in 10 fractions over 2 weeks, a three‐week rest, 3000 rad in 10 fractions over 2 weeks)
Study: 25567051
Drug: Avocado diet
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avocado diet (AV) including one fresh Hass avocado (136 g) per day
Study: 19561024
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow cells (BMCs) administered with each dose of cardioplegia antegradely into the coronaries
Study: 11930742
Drug: O2 insufflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2 insufflation for three times followed by complete absorption of CO2 after LC (Group C)
Study: 9391248
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose concentration at 12 mmol/l
Study: 8009346
Drug: Weekly physical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly physical exercise before pregnancy
Study: 31659541
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at a dose of 4 J/cm2
Study: 31659541
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at a dose of 2 J/cm2
Study: 27737649
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin (2 mg)
Study: 21382896
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg three times daily) for 6 weeks
Study: 16830289
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alpha 2b 1.5 microg/kg s.c. weekly plus ribavirin adjusted for patient's weight
Study: 3758142
Drug: 32.5 mg
Normalized name: phenol 32.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32.5 mg urapidil
Study: 3758142
Drug: 65 mg
Normalized name: opium 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg urapidil
Study: 3758142
Drug: 130 mg
Normalized name: pectin 130 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130 mg urapidil